

Patient Name : Mr MR.DUMMY	Sample Collected : Apr 26, 2024, 01:00 PM
DOB/Age/Gender : 23 Y/Male	Report Date : May 25, 2024, 02:46 PM.
Patient ID / UHID : 8052586/RCL7248936	Barcode No : SI485408
Referred By : Dr. X	Report Status : Final Report
Sample Type : Serum	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

U1RNP Antibodies

U1RNP ANTIBODIES <i>EIA, SERUM</i>	4.32	AU/ml	NEGATIVE: <12 EQUIVOCAL: 12-18 POSITIVE: >18
---------------------------------------	------	-------	--

Interpretation:
 The U1-snRNP complex is a small nuclear ribonucleoprotein particle composed of uridine rich (thus U) small nuclear RNA and a set of proteins: the 70 kDa U1-specific ribonucleoprotein plus proteins A and C (all formerly summarized as RNPs) and the Sm (Smith antigen which comprises eight proteins: B/B', D1, D2, D3, E, F and G. Because of its protein components, the Sm and RNPs, the complex is often named RNP/Sm complex. The U1- sn RNP complex is a part of the splicosomal complex, that facilitates the processing of pre-mRNA to mature mRNA in the nucleus. Antibodies against the 70 kDa protein of the U1-snRNP complex belong to the heterogenous group of anti-nuclear antibodies (ANA), which are associated with various autoimmune diseases. They are directed against various proteins of the nucleus. Indirect immunofluorescence test (IFT) on eucaryotic cells like HeLa has been the established method for the detection of ANAs. Single antibody specificities are distinguished by fluorescence patterns but more specific testing by ELISAs employing the target antigens are available too for a simple and reliable differentiation of ANAs. Antibodies against the 70 kDa U1-specific protein are found in 95% of mixed connective tissue diseases (MCTD) but do also occur in systemic lupus erythematosus (SLE) with a prevalence of 40%. Isolated occurrence of anti-70 kDa antibodies is typical for the Sharp syndrome, whilst antibodies against Sm are highly specific for systemic lupus erythematosus (SLE) and thus are included in diagnostic and classification criteria for SLE. Anti-SM antibodies are found in 20-30% of patients with SLE.

*** End Of Report ***

Disclaimer: Method given in report are only indicative and can be changed depending upon type of machine and kit available at time of testing. Not all tests at all locations are under NABL scope. Availability of tests under NABL scope varies from lab to lab.



Dr. Dummy



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
 Processing Lab :-

928-909-0609

ccsupport@redcliffelabs.com

www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

DISCLAIMER

This is a sample report provided for demonstration purposes only and does not represent an actual patient report. Test results, reference ranges, methodologies, instrumentation, and report formats may vary depending on the laboratory performing the test. The format and representation shown are indicative of reports generated by the National Reference Laboratory of Redcliffe Labs, Noida. This sample report should not be used for medical interpretation, diagnosis, or treatment decisions.